Skip to main content
. 2024 Mar 13;24:307. doi: 10.1186/s12879-024-09199-y

Table 1.

Baseline patient characteristics according to surgical prophylaxis exposure

Overall
N = 46 (100)
Standard prophylaxis
N = 24 (52)
Targeted prophylaxis
N = 22 (48)
p-value
Baseline characteristics
 Age, years 43 [33–52] 43 [35–50] 43 [31–55] 0.836
 Male gender, n (%) 24 (52) 16 (67) 8 (36) 0.075
 BMI, kg/m2 21 [18–24] 21 [19–24] 20 [18–24] 0.812
 Corticosteroids, n (%) 23 (50) 11 (46) 12 (55) 0.768
 O2 therapy, n (%) 38 (83) 21 (88) 17 (77) 0.451
 Diabetes, n (%) 11 (24) 6 (25) 5 (23) 0.999
 LAS 35 [34–39] 35 [34–39] 35 [33–39] 0.562
 Oto score 3 [1–5] 3 [1–5] 2 [2–6] 0.827
Underlying diseases
 Septica, n (%) 30 (65) 15 (63) 15 (68) 0.763
 Interstitialb, n (%) 7 (15) 4 (17) 3 (14) 0.999
 Obstructivec, n (%) 8 (17) 4 (17) 4 (18) 0.999
 Othersd, n (%) 1 (2) 1 (4) 0 (0) -
Previous colonization
 Recipient-related MS GN bacteria 24 (52) 13 (58) 9 (45) 0.395
 Recipient-related MDR GN bacteria 22 (48) 11 (42) 13 (55) 0.395
 Donor-related GN bacteriae 13 (28) 8 (33) 5 (23) 0.521
 Recipient-related viral colonization 2 (4) 0 (0) 2 (9) 0.476

Data are expressed as number and (percentage) or median and [interquartile range]. aSeptic: cystic fibrosis, bronchiectasis; bInterstitial: idiopathic pulmonary fibrosis, allergic extrinsic alveolitis, non-specific interstitial pneumonia, fibrosing emphysema, lymphocytic interstitial pneumonia, respiratory bronchiolitis interstitial lung; cObstructive: chronic obstructive pulmonary disease; dOthers: idiopathic pulmonary hypertension, veno-occlusive disease, connective tissue disease, α1-anti-trypsin deficiency, lymphangioleiomyomatosis, histiocytosis, sarcoidosis, graft versus host disease. Abbreviations: BMI, body mass index; n, number; O2, oxygen; LAS, lung allocation score; MS, multisensitive; GN, Gram-negative; MDR, multidrug-resistant; LT, lung transplant;